Search

Your search keyword '"Mugyenyi, Peter"' showing total 511 results

Search Constraints

Start Over You searched for: Author "Mugyenyi, Peter" Remove constraint Author: "Mugyenyi, Peter"
511 results on '"Mugyenyi, Peter"'

Search Results

1. Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4: 1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV

2. Translocated microbiome composition determines immunological outcome in treated HIV infection

3. The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models

4. Strengthening Institutional Research Administration in Uganda: A Case Study on Developing Collaborations among Academic and Research Institutions

5. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study

7. Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial

8. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study

9. Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial

10. Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial

11. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

12. Validation of World Health Organisation HIV/AIDS clinical staging in predicting initiation of antiretroviral therapy and clinical predictors of low CD4 cell count in Uganda.

14. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

17. Lymphoid tissue fibrosis is associated with impaired vaccine responses

18. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial

35. Strengthening institutional research administration in Uganda: a case study on developing collaborations among academic and research institutions

39. Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa

40. A qualitative analysis of the economic impact of HIV and antiretroviral therapy on individuals and households in Uganda

41. Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans

42. Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial

44. Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral-naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda

50. Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation

Catalog

Books, media, physical & digital resources